Actineer Appoints Radiopharmaceutical Executive Joseph Oliverio as President and CEO
Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL), has appointed Joseph Oliverio as President and CEO. Oliverio brings over three decades of leadership experience in nuclear medicine, medical devices, and radiopharmaceuticals, including positions at Ionetix, IMAGIN Molecular , and Positron (OTC: POSC).
The appointment comes as Actineer scales its Actinium-225 (Ac-225) manufacturing capabilities to supply the radiopharmaceutical industry. Oliverio's previous roles include VP of Clinical Operations at Ionetix, where he led cardiac radiopharmaceutical strategy and managed clinical trials, and President/CEO of IMAGIN Molecular At Positron , he managed a Neusoft joint venture, expanded PET scanner business, and led multiple funding rounds.
Oliverio holds an MBA in Technology Management and a BS in Nuclear Medicine Technology. The appointment aims to strengthen Actineer's position as a major global supplier of Ac-225, supporting the development of targeted alpha radiopharmaceuticals for cancer treatment.
Actineer, una joint venture tra ITM e Canadian Nuclear Laboratories (CNL), ha nominato Joseph Oliverio come Presidente e CEO. Oliverio porta con sé oltre tre decenni di esperienza nella leadership nel campo della medicina nucleare, dei dispositivi medici e dei radiofarmaceutici, avendo ricoperto ruoli in Ionetix, IMAGIN Molecular e Positron (OTC: POSC).
Questa nomina avviene mentre Actineer sta ampliando le proprie capacità di produzione di Actinium-225 (Ac-225) per fornire l'industria dei radiofarmaceutici. Tra le precedenti esperienze di Oliverio, ci sono il ruolo di VP delle Operazioni Cliniche in Ionetix, dove ha guidato la strategia dei radiofarmaceutici cardiaci e gestito studi clinici, e President/CEO di IMAGIN Molecular. In Positron, ha gestito una joint venture con Neusoft, espandendo il business degli scanner PET e guidando diversi round di finanziamento.
Oliverio possiede un MBA in Gestione della Tecnologia e una laurea in Tecnologia della Medicina Nucleare. Questa nomina mira a rafforzare la posizione di Actineer come fornitore globale di Ac-225, supportando lo sviluppo di radiofarmaceutici alfa mirati per il trattamento del cancro.
Actineer, una empresa conjunta entre ITM y Canadian Nuclear Laboratories (CNL), ha nombrado a Joseph Oliverio como Presidente y CEO. Oliverio aporta más de tres décadas de experiencia en liderazgo en medicina nuclear, dispositivos médicos y radiofármacos, incluidos puestos en Ionetix, IMAGIN Molecular y Positron (OTC: POSC).
El nombramiento se produce mientras Actineer amplía sus capacidades de fabricación de Actinio-225 (Ac-225) para abastecer a la industria de los radiofármacos. Los roles anteriores de Oliverio incluyen el de VP de Operaciones Clínicas en Ionetix, donde lideró la estrategia de radiofármacos cardíacos y gestionó ensayos clínicos, así como Presidente/CEO de IMAGIN Molecular. En Positron, gestionó una empresa conjunta con Neusoft, expandió el negocio de escáneres PET y dirigió múltiples rondas de financiamiento.
Oliverio tiene un MBA en Gestión de Tecnología y una licenciatura en Tecnología de Medicina Nuclear. El nombramiento tiene como objetivo fortalecer la posición de Actineer como un importante proveedor global de Ac-225, apoyando el desarrollo de radiofármacos alpha dirigidos para el tratamiento del cáncer.
Actineer는 ITM과 Canadian Nuclear Laboratories (CNL) 간의 합작 투자로, Joseph Oliverio를 사장 겸 CEO로 임명했습니다. Oliverio는 핵 의학, 의료 기기 및 방사성 의약품 분야에서 30년 이상의 리더십 경험을 보유하고 있으며, Ionetix, IMAGIN Molecular 및 Positron (OTC: POSC)에서의 직책이 포함됩니다.
이번 임명은 Actineer가 방사성 의약품 산업에 공급하기 위해 Actinium-225 (Ac-225)의 제조 능력을 확대하는 가운데 이루어졌습니다. Oliverio의 이전 역할에는 Ionetix에서의 임상 운영 VP가 포함되며, 이곳에서 심장 방사성 의약품 전략을 이끌고 임상 시험을 관리했습니다. 또한 그는 IMAGIN Molecular의 사장/CEO이기도 했고, Positron에서는 Neusoft와의 합작 회사를 관리하며 PET 스캐너 사업을 확대하고 여러 금융 라운드를 이끌었습니다.
Oliverio는 기술 관리 분야에서 MBA와 핵 의학 기술 분야에서 학사 학위를 가지고 있습니다. 이번 임명은 Actineer의 Ac-225의 주요 글로벌 공급업체로서의 입지를 강화하고, 암 치료를 위한 표적 알파 방사성 의약품의 개발을 지원하는 것을 목표로 하고 있습니다.
Actineer, une coentreprise entre ITM et les Laboratoires nucléaires canadiens (CNL), a nommé Joseph Oliverio Président et CEO. Oliverio apporte plus de trois décennies d'expérience en leadership dans le domaine de la médecine nucléaire, des dispositifs médicaux et des radiopharmaceutiques, ayant occupé des postes chez Ionetix, IMAGIN Molecular et Positron (OTC: POSC).
Cette nomination intervient alors qu'Actineer élargit ses capacités de production de l'Actinium-225 (Ac-225) pour fournir l'industrie des radiopharmaceutiques. Les rôles précédents d'Oliverio incluent VP des opérations cliniques chez Ionetix, où il a dirigé la stratégie des radiopharmaceutiques cardiaques et géré des essais cliniques, ainsi que Président/CEO d'IMAGIN Molecular. Chez Positron, il a géré une coentreprise avec Neusoft, élargi le marché des scanners PET et dirigé plusieurs cycles de financement.
Oliverio possède un MBA en gestion technologique et une licence en technologie de la médecine nucléaire. Cette nomination vise à renforcer la position d'Actineer en tant que fournisseur mondial majeur d'Ac-225, soutenant le développement de radiopharmaceutiques alpha ciblés pour le traitement du cancer.
Actineer, ein Joint Venture zwischen ITM und Canadian Nuclear Laboratories (CNL), hat Joseph Oliverio zum Präsidenten und CEO ernannt. Oliverio bringt über drei Jahrzehnte Führungserfahrung in der Nuklearmedizin, Medizintechnik und Radiopharmazeutika mit, darunter Positionen bei Ionetix, IMAGIN Molecular und Positron (OTC: POSC).
Die Ernennung erfolgt, während Actineer seine Actinium-225 (Ac-225) Produktionsmöglichkeiten ausbaut, um die Radiopharmaindustrie zu beliefern. Zu Oliverios früheren Positionen zählen der VP für Klinische Operationen bei Ionetix, wo er die Strategie für kardiologische Radiopharmazeutika leitete und klinische Studien verwaltete, sowie Präsident/CEO von IMAGIN Molecular. Bei Positron leitete er ein Joint Venture mit Neusoft, baute das PET-Scanner-Geschäft aus und führte mehrere Finanzierungsrunden.
Oliverio hat einen MBA in Technologiemanagement und einen Bachelor in Nuklearmedizin-Technologie. Ziel der Ernennung ist es, die Position von Actineer als wichtigen globalen Anbieter von Ac-225 zu stärken und die Entwicklung von gezielten Alpha-Radiopharmazeutika für die Krebsbehandlung zu unterstützen.
- Appointment of experienced executive with 30+ years in radiopharmaceutical industry
- Strategic positioning to scale Actinium-225 manufacturing capabilities
- Strong track record in managing joint ventures and funding rounds
- Expertise in clinical operations and regulatory submissions
- None.
Joseph Oliverio, President and CEO of Actineer (Photo: Business Wire)
Mr. Oliverio joins Actineer with over three decades of leadership experience across the nuclear medicine, medical device and radiopharmaceutical industries, including at Ionetix, IMAGIN Molecular Corporation and Positron Corporation (OTC: POSC). He takes the helm as Actineer moves forward with the scaling of its Ac-225 manufacturing capabilities and preparations to supply the radiopharmaceutical industry with this valuable alpha emitter.
“Actinium-225 holds promising potential in cancer treatment. With the appointment of Joseph Oliverio as President and CEO of Actineer, the Joint Venture is well-positioned to shape the future of this critical field,” said Dr. Andrew Cavey, CEO of ITM and Actineer Board Chairman. “His expertise will be instrumental in advancing the team’s efforts to ensure a reliable and scalable supply of Actinium-225, in an effort to meet the global demand.”
“With the appointment of Joseph as President and CEO, we are embarking on a new phase in Actineer’s corporate development,” said Jack Craig Jr., President and CEO of CNL and Actineer Board Member. “Joseph’s leadership experience across radiopharmaceutical organizations, particularly in driving growth strategies for alpha therapy segments and overseeing joint ventures, will be an invaluable asset as we ramp up our production efforts for GMP-grade Actinium-225 and begin supplying Actineer’s partners.”
Before joining Actineer, Mr. Oliverio held several senior executive roles in the radiopharmaceutical industry. Most recently, he served as VP of Clinical Operations at Ionetix Corporation, where he spearheaded their cardiac radiopharmaceutical clinical growth strategy, established new joint ventures with medical and private equity groups, contributed to their Targeted Alpha Therapy business segment, advised on regulatory product submissions, and managed their clinical trial. As President and CEO of IMAGIN Molecular Corporation, he led efforts to identify joint venture partners for cardiac and oncologic imaging. Prior to this, Mr. Oliverio was President and Chairman of the Board at Positron Corporation, where he managed a joint venture with Neusoft, expanded the PET scanner business, acquired IS2 Medical Systems, and successfully led multiple funding rounds. Mr. Oliverio holds an MBA in Technology Management from the University of
“Actineer is poised to become one of the major global suppliers of Actinium-225. I am privileged to work with such premier institutions as CNL and ITM and am eager to leverage my expertise and work together with the Actineer team to achieve this goal and thereby support the development of innovative targeted alpha radiopharmaceuticals for the treatment of challenging cancer indications,” said Joseph Oliverio, President and CEO of Actineer.
ITM’s and CNL’s combined expertise is the driving force behind Actineer’s mission to serve the radiopharmaceutical industry with Ac-225 as the demand for this scarce and promising alpha-emitter continues to rise.
About Actineer, Inc.
Actineer™ Inc. is a joint venture company between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM) dedicated to advancing Ac-225 technologies, quickly securing supply, and producing industrial-scale quantities of this valuable, rare medical radioisotope for the treatment of cancer. Founded in October 2023, Actineer™ Inc. together with its strong supply chain collaborators will progress Ac-225 development, production and processing technologies. It has established short-term production capabilities that is expected to lead to significantly boosting international supplies, while working long-term towards the construction of a new Actinium Production Facility (APF) in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116701006/en/
Actineer, Inc
Science Collaboration Centre
286 Plant Road
info@actineer.com
For media inquiries only: actineer@trophic.eu
Source: Actineer
FAQ
What experience does Joseph Oliverio bring to Actineer from his time at POSC?
How will Actineer's Actinium-225 production impact cancer treatment?
What are Joseph Oliverio's key achievements in the radiopharmaceutical industry?
How will Oliverio's appointment affect Actineer's manufacturing capabilities?
